Regis Healthcare Limited
Regis Healthcare Limited (REG.AX) Financial Performance & Income Statement Overview
Analyze Regis Healthcare Limited (REG.AX) financial statements (income, balance sheet, and cash flow) across both yearly and quarterly periods.
Regis Healthcare Limited (REG.AX) Income Statement & Financial Overview
Analyze Regis Healthcare Limited’s REG.AX earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 |
|---|---|---|---|---|
| Revenue | $533.98M | $475.66M | $394.72M | $376.76M |
| Cost of Revenue | $442.51M | $459.35M | $397.59M | $377.68M |
| Gross Profit | $91.47M | $16.31M | -$2.87M | -$910000.00 |
| Gross Profit Ratio | $0.17 | $0.03 | -$0.007 | -$0.002 |
| R&D Expenses | $0.00 | $0.00 | $0.00 | $0.00 |
| SG&A Expenses | $36.82M | $41.82M | $49.15M | $36.46M |
| Operating Expenses | $36.82M | $41.82M | $49.15M | $36.46M |
| Total Costs & Expenses | $479.33M | $501.17M | $446.74M | $414.13M |
| Interest Income | $2.69M | $1.29M | $526000.00 | $179000.00 |
| Interest Expense | $50.76M | $40.89M | $6.13M | $36.89M |
| Depreciation & Amortization | $65.02M | $63.05M | $63.12M | $63.35M |
| EBITDA | $102.21M | $89.24M | $64.46M | $62.92M |
| EBITDA Ratio | $0.19 | $0.08 | $0.03 | $0.07 |
| Operating Income | $54.65M | -$25.51M | -$52.03M | -$37.37M |
| Operating Income Ratio | $0.10 | -$0.05 | -$0.13 | -$0.10 |
| Other Income/Expenses (Net) | -$68.14M | -$54.74M | -$30.83M | -$66.11M |
| Income Before Tax | -$13.49M | -$14.61M | -$3.89M | -$36.49M |
| Income Before Tax Ratio | -$0.03 | -$0.03 | -$0.010 | -$0.10 |
| Income Tax Expense | -$4.22M | -$2.47M | -$1.35M | -$10.58M |
| Net Income | -$9.27M | -$12.14M | -$2.54M | -$25.91M |
| Net Income Ratio | -$0.02 | -$0.03 | -$0.006 | -$0.07 |
| EPS | -$0.03 | -$0.04 | -$0.008 | -$0.09 |
| Diluted EPS | -$0.03 | -$0.04 | -$0.008 | -$0.09 |
| Weighted Avg Shares Outstanding | $301.06M | $300.98M | $300.91M | $300.87M |
| Weighted Avg Shares Outstanding (Diluted) | $301.10M | $300.98M | $300.91M | $300.87M |
The company's financials show resilient growth, with revenue advancing from $376.76M in Q2 2023 to $533.98M in Q4 2024. Gross profit remained healthy with margins at 17% in Q4 2024 compared to -0% in Q2 2023. Operating income hit $54.65M last quarter, sustaining a consistent 10% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $102.21M. Net income rose to -$9.27M, while earnings per share reached -$0.03. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan